Advances in GI Cancer Care: How to Consider the Latest Drugs and Strategies

In this new edition of the Cancer Center Live Series, three UCSF specialists present exciting updates on difficult-to-treat gastrointestinal malignancies, including pancreatic cancer, peritoneal metastases and advanced biliary tract cancers.


· Why germline testing is important and how to navigate new chemo options for metastatic pancreatic cancer, such as NALIRIFOX – recently approved as a first-line treatment – as well as targeted therapies, such as PARP inhibitors

· Why peritoneal metastasis can progress with frightening speed, the promise of CRS/HIPEC (cytoreductive surgery + hyperthermic intraperitoneal chemotherapy) for increasing survival, and which colon cancer patients might benefit from CRS/HIPEC

· How the last few years have seen rising rates of biliary tract cancers but also newly approved chemo protocols and immunotherapy options for certain patient groups, with benefits such as lengthening response time

Bonus: A look at current clinical trials on these challenging cancers


March 15, 2024

Created by

UCSF MedConnection

Related Presenters

Andrew Ko, MD

Andrew Ko, MD

Colorectal and gastrointestinal cancer specialist

View Full Profile

R. Kate Kelley, MD

R. Kate Kelley, MD

Gastrointestinal oncologist

View full profile

Mohamed Adam, MD

Mohamed Adam, MD

Gastrointestinal cancer surgeon

View full profile